Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Centre Oscar Lambret
French Africa Pediatric Oncology Group
Children's Oncology Group
Children's Oncology Group
Seattle Children's Hospital
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Children's National Research Institute
Mayo Clinic
St. Jude Children's Research Hospital
Cue Biopharma
Baylor College of Medicine
Hoffmann-La Roche
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Seattle Children's Hospital
Seattle Children's Hospital
Milton S. Hershey Medical Center
Baylor College of Medicine
St. Jude Children's Research Hospital
Assistance Publique - Hôpitaux de Paris
Nationwide Children's Hospital
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
Baylor College of Medicine
University Hospital, Antwerp
Children's Hospital of Philadelphia
Children's Oncology Group
City of Hope Medical Center
RenJi Hospital
Birmingham Women's and Children's NHS Foundation Trust
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Ann & Robert H Lurie Children's Hospital of Chicago
Children's Hospitals and Clinics of Minnesota
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's National Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University